메뉴 건너뛰기




Volumn 375, Issue 16, 2016, Pages 1591-1592

Adaptive randomization of neratinib in early breast cancer

Author keywords

[No Author keywords available]

Indexed keywords

NERATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; QUINOLINE DERIVATIVE;

EID: 84992028261     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1609993     Document Type: Letter
Times cited : (10)

References (4)
  • 1
    • 84978140851 scopus 로고    scopus 로고
    • I-SPY 2 - a glimpse of the future of phase 2 drug development?
    • Harrington D, Parmigiani G. I-SPY 2 - a glimpse of the future of phase 2 drug development? N Engl J Med 2016; 375: 7-9.
    • (2016) N Engl J Med , vol.375 , pp. 7-9
    • Harrington, D.1    Parmigiani, G.2
  • 2
    • 0023185342 scopus 로고
    • Equipoise and the ethics of clinical research
    • Freedman B. Equipoise and the ethics of clinical research. N Engl J Med 1987; 317: 141-5.
    • (1987) N Engl J Med , vol.317 , pp. 141-145
    • Freedman, B.1
  • 3
    • 84924915397 scopus 로고    scopus 로고
    • Are outcome-adaptive allocation trials ethical?
    • Hey SP, Kimmelman J. Are outcome-adaptive allocation trials ethical? Clin Trials 2015; 12: 102-6.
    • (2015) Clin Trials , vol.12 , pp. 102-106
    • Hey, S.P.1    Kimmelman, J.2
  • 4
    • 84978160766 scopus 로고    scopus 로고
    • I-SPY 2 - toward more rapid progress in breast cancer treatment
    • Carey LA, Winer EP. I-SPY 2 - toward more rapid progress in breast cancer treatment. N Engl J Med 2016; 375: 83-4.
    • (2016) N Engl J Med , vol.375 , pp. 83-84
    • Carey, L.A.1    Winer, E.P.2


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.